COMORBIDITIES AND PROCEDURAL OUTCOMES IN STEMI PATIENTS WITH AND WITHOUT A HISTORY OF DRUG ABUSE

IF 4.3 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS
Sai Allu MD
{"title":"COMORBIDITIES AND PROCEDURAL OUTCOMES IN STEMI PATIENTS WITH AND WITHOUT A HISTORY OF DRUG ABUSE","authors":"Sai Allu MD","doi":"10.1016/j.ajpc.2024.100794","DOIUrl":null,"url":null,"abstract":"<div><h3>Therapeutic Area</h3><div>ASCVD/CVD Risk Factors</div></div><div><h3>Background</h3><div>Patients with a history of drug abuse are at increased risk for cardiovascular events, including ST-segment elevation myocardial infarction (STEMI). However, the prevalence of comorbidities and procedural outcomes in this population remain understudied. This study aimed to compare the prevalence of comorbidities and procedural outcomes in STEMI patients with and without a history of drug abuse.</div></div><div><h3>Methods</h3><div>A total of 180,265 patients diagnosed with STEMI in 2020 with NIS data using SPSS were included in this registry study. Patients were categorized into two groups: those with a history of drug abuse (n=8,843; 4.9%) and those without (n=171,422; 95.1%). The prevalence of comorbidities, including congestive heart failure, diabetes, and renal failure, was compared between the two groups using odds ratios (OR) and 95% confidence intervals (CI). Procedural outcomes, such as percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG), were also analyzed.</div></div><div><h3>Results</h3><div>Drug users had a higher prevalence of congestive heart failure (69% vs. 62%) and renal failure (31% vs. 39%) compared to non-drug users. However, diabetes was less prevalent among drug users (14% vs. 43%). Non-drug users with congestive heart failure had higher odds of mortality (OR 1.353, 95% CI: 1.301-1.408) compared to those without, while drug users had lower odds (OR 0.724, 95% CI: 0.581-0.902). No significant differences in mortality odds were observed for diabetes in either group. Non-drug users with renal failure had higher odds of mortality (OR 1.266, 95% CI: 1.218-1.314), while drug users exhibited no significant change. Among patients undergoing procedures, non-drug users had higher rates of single-vessel PCI (0.436% vs. 0.339%), double-vessel PCI (0.080% vs. 0.034%), and single-vessel CABG (0.046% vs. 0.034%) compared to drug users.</div></div><div><h3>Conclusions</h3><div>This study highlights the differences in comorbidities and procedural outcomes between STEMI patients with and without a history of drug abuse. Drug users had a higher prevalence of congestive heart failure and renal failure but a lower prevalence of diabetes compared to non-drug users. Non-drug users with congestive heart failure and renal failure had higher odds of mortality, while drug users had lower or no significant change in mortality odds. Non-drug users also had higher rates of PCI and CABG procedures compared to drug users. These findings emphasize the need for tailored management strategies considering the unique comorbidity profiles and procedural outcomes in STEMI patients with a history of drug abuse.</div></div>","PeriodicalId":72173,"journal":{"name":"American journal of preventive cardiology","volume":"19 ","pages":"Article 100794"},"PeriodicalIF":4.3000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of preventive cardiology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666667724001624","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Therapeutic Area

ASCVD/CVD Risk Factors

Background

Patients with a history of drug abuse are at increased risk for cardiovascular events, including ST-segment elevation myocardial infarction (STEMI). However, the prevalence of comorbidities and procedural outcomes in this population remain understudied. This study aimed to compare the prevalence of comorbidities and procedural outcomes in STEMI patients with and without a history of drug abuse.

Methods

A total of 180,265 patients diagnosed with STEMI in 2020 with NIS data using SPSS were included in this registry study. Patients were categorized into two groups: those with a history of drug abuse (n=8,843; 4.9%) and those without (n=171,422; 95.1%). The prevalence of comorbidities, including congestive heart failure, diabetes, and renal failure, was compared between the two groups using odds ratios (OR) and 95% confidence intervals (CI). Procedural outcomes, such as percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG), were also analyzed.

Results

Drug users had a higher prevalence of congestive heart failure (69% vs. 62%) and renal failure (31% vs. 39%) compared to non-drug users. However, diabetes was less prevalent among drug users (14% vs. 43%). Non-drug users with congestive heart failure had higher odds of mortality (OR 1.353, 95% CI: 1.301-1.408) compared to those without, while drug users had lower odds (OR 0.724, 95% CI: 0.581-0.902). No significant differences in mortality odds were observed for diabetes in either group. Non-drug users with renal failure had higher odds of mortality (OR 1.266, 95% CI: 1.218-1.314), while drug users exhibited no significant change. Among patients undergoing procedures, non-drug users had higher rates of single-vessel PCI (0.436% vs. 0.339%), double-vessel PCI (0.080% vs. 0.034%), and single-vessel CABG (0.046% vs. 0.034%) compared to drug users.

Conclusions

This study highlights the differences in comorbidities and procedural outcomes between STEMI patients with and without a history of drug abuse. Drug users had a higher prevalence of congestive heart failure and renal failure but a lower prevalence of diabetes compared to non-drug users. Non-drug users with congestive heart failure and renal failure had higher odds of mortality, while drug users had lower or no significant change in mortality odds. Non-drug users also had higher rates of PCI and CABG procedures compared to drug users. These findings emphasize the need for tailored management strategies considering the unique comorbidity profiles and procedural outcomes in STEMI patients with a history of drug abuse.
有吸毒史和无吸毒史的干细胞成像患者的合并症和程序结果
治疗领域心血管疾病/心血管疾病风险因素背景有吸毒史的患者发生心血管事件(包括 ST 段抬高型心肌梗塞)的风险更高。然而,对这一人群的合并症发生率和手术结果的研究仍然不足。本研究旨在比较有和无药物滥用史的 STEMI 患者的合并症发生率和手术结果。方法本登记研究共纳入了 180,265 名 2020 年诊断为 STEMI 的患者,这些患者的 NIS 数据使用了 SPSS。患者分为两组:有药物滥用史的患者(n=8,843;4.9%)和无药物滥用史的患者(n=171,422;95.1%)。使用几率比(OR)和 95% 置信区间(CI)比较了两组患者的合并症患病率,包括充血性心力衰竭、糖尿病和肾功能衰竭。结果与非用药者相比,用药者的充血性心力衰竭(69% 对 62%)和肾功能衰竭(31% 对 39%)发病率更高。然而,糖尿病在吸毒者中的发病率较低(14% 对 43%)。与没有充血性心力衰竭的人相比,非药物使用者的死亡几率更高(OR 1.353,95% CI:1.301-1.408),而药物使用者的几率较低(OR 0.724,95% CI:0.581-0.902)。两组糖尿病患者的死亡几率均无明显差异。肾功能衰竭的非用药者的死亡几率更高(OR 1.266,95% CI:1.218-1.314),而用药者则无明显变化。在接受手术的患者中,与吸毒者相比,非吸毒者的单血管 PCI(0.436% vs. 0.339%)、双血管 PCI(0.080% vs. 0.034%)和单血管 CABG(0.046% vs. 0.034%)发生率更高。与非吸毒者相比,吸毒者的充血性心力衰竭和肾功能衰竭发病率较高,但糖尿病发病率较低。非吸毒者出现充血性心力衰竭和肾功能衰竭的死亡率较高,而吸毒者的死亡率较低或无明显变化。与用药者相比,非用药者接受 PCI 和 CABG 手术的比例也更高。这些发现强调,考虑到有吸毒史的 STEMI 患者独特的合并症情况和手术结果,有必要制定量身定制的管理策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
American journal of preventive cardiology
American journal of preventive cardiology Cardiology and Cardiovascular Medicine
CiteScore
6.60
自引率
0.00%
发文量
0
审稿时长
76 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信